Lanean...
Novel immunotherapies in lymphoid malignancies
The success of the anti-CD20 monoclonal antibody rituximab in the treatment of lymphoid malignancies provided proof-of-principle for exploiting the immune system therapeutically. Since the FDA approval of rituximab in 1997, several novel strategies that harness the ability of T cells to target cance...
Gorde:
| Argitaratua izan da: | Nat Rev Clin Oncol |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2015
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916838/ https://ncbi.nlm.nih.gov/pubmed/26525683 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2015.187 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|